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Background:  Transjugular  Intrahepatic  Portosystemic  Shunt  (TIPS)  is  a  well-established  treatment  for
complications  of  portal  hypertension.
Aims:  To analyze  the  impact  of  TIPS  on  virologic  response  and  safety  profile  in patients  treated  with
direct-acting  antivirals  (DAAs).
Methods:  We analyzed  data  from  HCV-positive  cirrhotic  patients  treated  with  DAAs.  Twenty-one  patients
with previous  TIPS  placement  were  compared  with  42 matched  subjects  without  TIPS. Logistic  regression
was  used  to identify  predictors  of  hepatic  function  worsening  and  adverse  events.
Results:  No  differences  were  found  between  the  two groups  in particular  regarding  sustained  virologic
response  (92.5  and  97.6%  in TIPS  vs  no-TIPS,  p = 0.559).  Model  for End-stage  Liver  Disease  (MELD)  of  both
TIPS and  no-TIPS  groups  declined  from  baseline  to week  24  of  follow-up  (from  12.5 ± 3.5 to  10.8  ± 3.4
and  from  11.1  ± 3.5  to 10.3  ± 3.4,  p = 0.044  and  0.025).  There  were  no  differences  in  adverse  event rates.
At  univariate  analysis,  age  was associated  with  MELD  increase  from  baseline  to week  24  (OR 1.111,  95%
CI  1.019-1.211,  p =  0.017),  and  patients  with  higher  baseline  MELD  developed  serious  adverse  events
more  frequently  (OR  0.815,  95% CI 0.658–1.010,  p = 0.062).  Patients  with  or  without  TIPS  did  not  show
differences  in  transplant-free  survival.
Conclusion:  TIPS  placement  does  not  affect  virologic  response  and  clinical  outcome  of patients  receiving
DAAs.
© 2018  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.. IntroductionPlease cite this article in press as: S. Gitto, F. Vizzutti, F. Schepis, et al.. T
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About 3% of the world population is infected with hepatitis C
irus (HCV) infection and 150.000 new infections are registered
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590-8658/© 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Allevery year in Western countries [1]. Twenty percent of patients
with chronic hepatitis C (CHC) develop cirrhosis, and 700.000
deaths associated with complications of liver disease occur every
year [2]. Until a few years ago, antiviral therapy based on inter-
feron in association with ribavirin (RBV) was the only approach for
infected patients, with modest rates of sustained virologic response
(SVR) and significant side effects [3]. During the last few years, new
antiviral molecules with a direct action against the virus have beenransjugular Intrahepatic Portosystemic Shunt does not affect the
ed cirrhosis: A real-life, case-control study. Dig Liver Dis (2019),
developed, resulting in a dramatic change in the management of
CHC [3]. In fact, most direct-acting antiviral (DAA) schedules induce
high SVR rates with excellent safety profiles. At difference with
 rights reserved.
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nterferon-based antiviral therapy, DAAs can be used in patients
ith advanced liver disease with good SVR rates [4] and a positive
mpact on patient survival [5]. Nonetheless, Curry et al. [6] reported
hat in patients in Child-Pugh-Turcotte (CTP) class B treated with
AAs, satisfactory SVR rate (83–94%) were associated with a rel-
vant number of serious adverse events (SAE) compared to the
ame regimens in patients with chronic hepatitis or compensated
irrhosis (16–19% vs 2%) [6,7].
Transjugular Intrahepatic Portosystemic Shunt (TIPS) is a lead-
ng treatment option for the complications of portal hypertension.
IPS is indicated in portal hypertensive bleeding, refractory ascites
nd vascular liver diseases, resulting in improvement of patient
urvival [8–12]. Notably, TIPS strongly modifies splanchnic hemo-
ynamics, determining substantial porto-systemic shunting [8].
IPS placement might influence the pharmacokinetics of different
rugs [13–15], and this is theoretically possible also for DAAs. The
afety profile represents another open issue, considering the high
ates of SAEs in patients with advanced liver disease [6]. These
spects have never been previously investigated.
In this study, we evaluated the impact of TIPS on SVR rate, drug
afety profile and liver function in HCV-positive cirrhotic patients
reated with DAAs.
. Materials and methods
We  analyzed biochemical, virological and clinical data of HCV-
ositive cirrhotic patients with functioning TIPS, consecutively
reated with DAA-based therapies from September 2014 to April
017. In all cases, TIPS was placed before starting DAA therapy. Cir-
hotic patients without TIPS treated with DAAs in the same period
f time were used as comparison. They were selected among HCV
ositive patients consecutively treated in the four tertiary par-
icipating centers, according to sex, age (±3 years) and CTP class
match 1:2). DAA schedule and treatment length were established
ollowing the recommendations of the Italian Medicines Agency
ommittee [16].
Enrollment criteria were age >18 years and HCV infection as
stablished by both positive serum HCV antibody and serum HCV-
NA, using a real-time polymerase chain reaction-based method.
atients had evidence of cirrhosis as assessed by liver biopsy,
ibration-controlled transient elastography with FibroScan
®
, or
y the presence of complications. Other causes of liver disease
ncluding alcohol abuse, and previous liver transplantation were
xclusion criteria.
In all patients with previous TIPS placement, shunt patency was
ocumented by radiologic follow-up. All enrolled patients under-
ent at least one Doppler ultrasound within six months from the
eginning of antiviral therapy with the following signs of optimal
unction [17]: whole color saturation in three segments of the stent
portal, midportion, and hepatic sites) without any evidence of fill-
ng defects or focal aliasing; high-velocity turbulent flow into the
tent with a gradual velocity shift during respiration; hepatofugal
ow in the portal vein branches; hepatic artery flow increase.
Laboratory assessment, including HCV-RNA levels, was con-
ucted at baseline, end of antiviral treatment, and 12 and 24 weeks
fter the end of DAA. Model for End-Stage Liver Disease (MELD)
nd MELD corrected by serum sodium (MELD-Na) were calculated
t all time points. Delta values were calculated (week 24 of follow-
p − baseline) for all the main laboratory values. HCV-RNA levels
ere measured with COBAS
®
AmpliPrep/COBAS
®
TaqMan
®
HCV
uantitative Test, v2.0 (limit 15 IU/ml).Please cite this article in press as: S. Gitto, F. Vizzutti, F. Schepis, et al.. T
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We registered DAA-related and unrelated adverse events (AEs)
untoward medical occurrence associated with the use of antiviral
herapy) and SAEs (death, a life-threatening AE, inpatient hospital-
zation or prolongation of existing hospitalization, a persistent or PRESS
 and Liver Disease xxx (2019) xxx–xxx
significant incapacity or substantial disruption of the ability to con-
duct normal life functions) [18]. The study protocol conformed to
the ethical guidelines of the 1975 Declaration of Helsinki. Patients
gave their written informed consent to undergo antiviral therapy
with DAAs.
2.1. Statistical analysis
A physician trained in statistics encoded all samples into a ded-
icated database in an anonymous form. Data are expressed as the
mean (±standard deviation) or median (with range), as applicable.
Confidence interval (CI) is shown where appropriate. Comparisons
between groups were made by Chi square-test and Fisher’s exact
test for qualitative variables, and Mann–Whitney U-test for con-
tinuous ordinal data, respectively. Wilcoxon test was  utilized to
assess tendencies and specific rank test for significance. Logistic
regression was performed to identify the predictors of liver func-
tion impairment, AEs and SAEs. Presence of TIPS was  analyzed as
potential predictor in all outcome analyses. A significance level of
0.05 was  considered for all tests. The SPSS software version 21.0
(MJ  Norusis, Chicago, US) was used for all statistical analyses.
3. Results
3.1. Baseline characteristics
We  enrolled 21 HCV-positive cirrhotic patients with previous
TIPS placement and 42 cirrhotic subjects without TIPS, matched
for gender, age and CTP class. The main demographic and base-
line clinical characteristics of the two groups (TIPS and no-TIPS)
are summarized in Table 1. Additional clinical and technical data
of patients included in the TIPS group are reported in Supplemen-
tary Table 1. Notably, a fraction of patients had under-dilated TIPS
according to an approach described in a recently published study
[19]. Patients with TIPS and the counterparts were comparable for
all other clinical and virologic characteristics. Genotype 1b was  the
most represented, and sofosbuvir/ledipasvir the most frequently
used antiviral schedule. RBV was  added to DAA in approximately
half of the cases, in both groups.
3.2. Virologic response
All patients concluded the antiviral therapy. All patients, regard-
less of the presence of TIPS, reached the SVR12 but not all
maintained the virologic response at 24 weeks of follow-up (SVR24
92.5% vs 97.6% in TIPS and no-TIPS, respectively, p = 0.559). One
patient in each group had a virologic relapse: in the TIPS group, a
49 years old male, genotype 4, CTP class A, treated for 24 weeks
with sofosbuvir/ledipasvir without RBV; in the no-TIPS group, a 42
years old male, genotype 1a, CTP class B, treated for 24 weeks with
sofosbuvir/ledipasvir without RBV.
3.3. Changes in laboratory parameters and liver function
The behavior of laboratory tests at baseline (T0), end of treat-
ment (EOT) and week 24 of follow-up (W24) is reported in Table 2.
Patients with TIPS and no-TIPS were in general comparable for
all laboratory assessments, although those with TIPS had higher
median values of total bilirubin at EOT and at W24  in comparison
with patients without TIPS.
Analyzing the modifications along the three time points, amino-
transferases and GT levels decreased in both groups, while totalransjugular Intrahepatic Portosystemic Shunt does not affect the
ed cirrhosis: A real-life, case-control study. Dig Liver Dis (2019),
bilirubin significantly declined only in patients without TIPS. Mean
MELD scores at each time point and their trend during and after
antiviral therapy are reported in Table 2 and in Fig. 1. Patients of
the two  groups had statistically equivalent MELD and MELD-Na
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Table  1
Baseline characteristics of patients included in the TIPS and no-TIPS groups.
TIPS no-TIPS 2-Fisher/MW-U
P value
N 21 42
Male n (%) 18 (85.7) 36 (85.7) 1.000
Age  (years, mean ± SD) 58 ± 10 61 ± 10 0.385
Genotype n (%)
1a 4 (19) 8 (19) 1.000
1b  9 (42.9) 21 (50) 0.395
2  1 (4.8) 2 (4.8) 1.000
3  3 (14.3) 8 (19) 0.564
4  4 (19) 3 (7.1) 0.160
HCV-RNA (UI/ml) (median, R) 352977. 8740–12723486 380000. 2750–12295107 0.683
CTP  score n (%)
A6 9 (42.8) 18 (42.8) 1.000
B7  3 (14.3) 15 (35.7) 0.137
B8  8 (38.1) 5 (11.9) 0.023
B9  0 (0) 2 (4.8) 0.548
C10  1 (4.8) 2 (4.8) 1.000
MELD  (mean ± SD) 12.5 ± 3.5 11.1 ± 3.5 0.177
MELD-Na (mean ± SD) 13.6 ± 3.5 12.4 ± 5.2 0.055
DAA  regimen n (%)
SOF/SIM 0 2 (4.8) 0.441
SOF/LPV 11 (52.4) 18 (42.9) 0.327
SOF/DCV 7 (33.3) 14 (33.3) 1.000
SOF  2 (9.5) 3 (7.1) 0.545
OBV/PTV/RTV/DSV 0 4 (9.5) 0.188
OBV/PTV/RTV 1 (4.8) 1 (2.4) 0.559
RBV  n (%) 9 (42.9) 20 (47.6) 0.465
Length  of therapy 12/24 week n (%) 0 (0)/21 (100%) 6 (14.3)/36 (85.7) 0.077
TIPS: Transjugular Intrahepatic Portosystemic Shunt; 2: Chi square; MW-U: Mann–Whitney U test; SD: standard deviation; R: range; CTP: Child-Turcotte-Pugh; MELD:
Model  for End-stage Liver Disease; SOF: sofosbuvir; SMV: simeprevir; LPV: ledipasvir; DCV: daclatasvir; OBV: ombitasvir; PTV: paritaprevir; RTV: ritonavir; DSV: dasabuvir;
RBV:  ribavirin.
Table 2
Laboratory parameters in cirrhotic patients with or without TIPS undergoing therapy with DAA.
TIPS no-TIPS
T0 EOT W24  T0 EOT W24
PLT (×109/mmc) (median, R) 79. 36–161 78. 33–172 78. 36–164 98. 19–222 92, 19–259 98. 20–206
Bilirubin (mg/dl) (median, R) 1.8. 0.8–7.2 1.7. 1.1–4.6b 1.3. 0.5–3.4b 1.3. 0.4–8.6 1.3, 0.2–6.7a 1. 0.4–5.5a
AST (IU/ml) (median, R) 61. 28–154 31. 14–63a 30. 17–55a 73. 21–519 28, 16–66a 25. 13–71a
ALT (IU/ml) (median, R) 47. 21–151 23. 9–48a 21. 10–52a 60. 11–405 20, 11–48a 21. 10–58a
GT (IU/ml) (median, R) 53. 10–303 36. 7–246a 33. 8–120a 67. 16–303 41, 12–121a 42. 12–119a
ALP (IU/ml, median, R) 100. 62–233 99. 46–193 104. 57–200b 126. 58.490 123, 59–635a 157. 22–801
Creatinine (mg/dl, mean ± SD) 0.9 ± 0.2 0.8 ± 0.3 1 ± 0.4 0.9 ± 0.3 0.9 ± 0.3 0.9 ± 0.3
MELD  score (mean ± SD) 12.5 ± 3.5 12.7 ± 3b 10.8 ± 3.4a 11.1 ± 3.5 10.5 ± 3.4a 10.3 ± 3.4a
MELD-Na score (mean ± SD) 13.6 ± 3.5 13.7 ± 3.2b 11.7 ± 3.4a 12.4 ± 5.2 11 ± 4.2 10.4 ± 3.4a
T0: start of DAA treatment; EOT: end of antiviral therapy; W24: week 24 of follow-up after the end of antiviral therapy; R: range; PLT: platelets; AST: aspartate aminotrans-
ferase;  ALT: alanine aminotransferase; GT: gamma  glutamyl transferase; ALP: alkaline phosphatase; MELD: Model for End-Stage Liver Disease.
a Significant difference with respect to T0 (Wilcoxon test, p < 0.05).
b Significant difference compared to the same time point in no-TIPS (Mann–Whitney U test, p < 0.05).
Table 3
Comparison of changes in laboratory parameters before and after antiviral treatment in cirrhotic patients with or without TIPS.
Delta value (W24 − T0) TIPS no-TIPS P value
PLT (×109/mmc) median (R) +2 (−61 to +54) +4 (−42 to +49) 0.406
Bilirubin (mg/dl) median (R) −0.4 (−6.7 to +2.5) −0.3 (−15 to +1) 0.994
AST  (IU/ml) median (R) −29 (−137 to +9) −48 (−448 to −1) 0.055
ALT  (IU/ml) median (R) −25 (−144 to +12) −41 (−347 to +35) 0.079
GT  (IU/ml) median (R) −20 (−141 to +37) −22 (−218 to +99) 0.569
ALP  (IU/ml) median (R) −6 (−141 to +39) +8 (−153 to +347) 0.354
Creatinine (mg/dl) mean ± SD +0.1 ± 0.2 +0.05 ± 0.2 0.331
MELD  score mean ± SD −1.7 ± 3.4 −0.7 ± 2.6 0.039
MELD-Na score mean ± SD −2 ± 3.9 −2 ± 5.1 0.433
T herap
t : alka
E
s
h
j0: start of DAA treatment; W24: week 24 of follow-up after the end of antiviral t
ransferase; ALT: alanine aminotransferase; GT: gamma  glutamyl transferase; ALP
nd-Stage Liver Disease corrected by serum sodium.Please cite this article in press as: S. Gitto, F. Vizzutti, F. Schepis, et al.. T
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cores at T0 and W24. Patients with TIPS showed a significantly
igher mean MELD and MELD-Na at EOT in comparison with sub-
ects with no-TIPS. Mean MELD score dropped from T0 to EOT andy; MW-U: Mann–Whitney U test; R: range; PLT: platelets; AST: aspartate amino-
line phosphatase; MELD: Model for End-Stage Liver Disease; MELD-Na: Model forransjugular Intrahepatic Portosystemic Shunt does not affect the
ed cirrhosis: A real-life, case-control study. Dig Liver Dis (2019),
from T0 to W24  in the control group. Patients with TIPS showed a
significant decrease of mean MELD from T0 to W24  but not from
T0 to EOT. In both groups, MELD-Na significantly decreased from
ARTICLE IN PRESSG ModelYDLD-3926; No. of Pages 5
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Fig. 1. Distribution of MELD score (ranging from 6 to 40, with higher values indicat-
ing more advanced liver disease) according to the previous TIPS placement. MELD
at  beginning of antiviral treatment (dark grey bar), MELD calculated at the end of
antiviral therapy (light grey bar), MELD at week 24 from the end of treatment (white
bar). The horizontal bar inside the box indicates the median value. The points rep-
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Table 4
Adverse events in cirrhotic patients with or without TIPS undergoing treatment with
DAA.
TIPS no-TIPS 2-Fisher
P value
N 21 42
AEs (overall) n (%) 9 (42.9) 13 (31) 0.255
AEs  (DAA-related) n (%) 3 (14.3) 10 (23.8) 0.297
Fatigue 3 (100) 7 (70)
Skin rash 0 2 (20)
Nausea 0 1 (10)
AEs (not DAA-related) n (%) 6 (28.6) 3 (7.1) 0.031
Ascites 2 (33.3) 0
Rectal bleeding 1 (16.7) 0
Skin infection 1 (16.7) 0
Hepatic Hencephalopathy 1 (16.7) 0
Depression 1 (16.7) 2 (66.7)
Anaemia 0 1 (33.3)
Withdrawal of antiviral for AE 0 0 1.000
SAEs (overall) n (%) 1 (4.8) 6 (14.3) 0.248
SAEs (DAA-related) n (%) 0 0 1.000
SAEs (not DAA-related) n (%) 1 (4.8) 6 (14.3) 0.248
HCC 1 (100) 3 (50)
Liver failure 0 1 (16.7)
SBP 0 1 (16.7)
Portal thrombosis 0 1 (16.7)
Withdrawal of antiviral for SAE n (%) 0 0 1.000
Death during treatment n (%) 0 0 1.000
Death during 2-year follow-up n (%) 0 1 (2.4) 0.667
LT  during treatment n (%) 0 0 1.000
LT  during 2-year follow-up n (%) 3 (14.3) 1 (2.4) 0.104esent the outliers, defined as values not falling in the inner fences. The asterisks
re the extreme outliers, defined as values more than three times the height of the
oxes.
0 to W24. Delta values (W24 − T0) of the analyzed laboratory
arameters are reported in Table 3. Patients with TIPS showed a
ignificantly greater mean delta-MELD than patients without TIPS.
MELD score declined from T0 to W24  in the vast majority of
atients while it increased in 14.3% of patients with TIPS (3/21) and
n 16.7% of no-TIPS (7/42) (p = 0.559). At univariate analysis, only
atients’ age was significantly associated with the increase in MELD
core (from T0 to W24) [Odds Ratio (OR) 1.111, 95% CI 1.019–1.211,
 = 0.017]. In particular, mean age was 67 ± 7 in patients with
ncreased MELD, and 59 ± 10 years in those who decreased MELD.
he presence of TIPS or time between TIPS placement and start of
AA therapy did not emerge as significant variables either in the
reliminary univariate test or in the multivariate model.
.4. Safety
The main safety outcomes are summarized in Table 4. Compar-
ng TIPS and no-TIPS, no significant differences were found in the
ncidence of AE. The most common DAA-related AE was fatigue.
CC occurrence during antiviral therapy was the most frequent
AE unrelated to DAA. No DAA-related SAEs were registered. No
atients discontinued treatment prematurely because of an AE or
AE.
Male gender was the only feature that tended to be associated
ith the occurrence of AE (OR 0.148, 95% CI 0.018–1.241, p = 0.078).
Es were reported in 40.4% of males (21/52) and in 9.1% of females
1/11). No predictors of DAA-related AE were detected.
At univariate analysis for the predictors of SAE, MELD score at
0 emerged as the only factor with a P value <0.1 (OR 0.815, 95% CI
.658–1.010, p = 0.062). Patients who experienced a SAE showed a
ean baseline MELD score of 14 ± 5, compared to 11 ± 3 in the other
atients. The presence of TIPS or time between TIPS placement and
tart of DAA therapy did not emerge as significant variables either
n the preliminary univariate test or in the multivariate model.
.5. Long-term outcomePlease cite this article in press as: S. Gitto, F. Vizzutti, F. Schepis, et al.. T
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No patient died or was transplanted during the antiviral ther-
py. During the 2-year follow-up period, 1 patient died (no-TIPS
roup) while 3 patients with TIPS and 1 no-TIPS were transplanted.
wo-year cumulative survival of patients with TIPS was  100% while2: Chi square; AE: adverse event; DAA: direct acting antivirals; SAE. serious adverse
event; HCC: hepatocellular carcinoma; SBP: spontaneous bacterial peritonitis; LT:
Liver Transplant.
survival of no-TIPS was 97.4% (p = 0.549). Death and transplanta-
tion occurred in all cases for progression of the underlying liver
disease, and were not related to DAA therapy. The patient who
died was  a 60 years old male, genotype 1b, CTP B, treated with
ombitasvir/paritaprevir/ritonavir plus dasabuvir and RBV for 12
weeks with achievement of RVR, SVR12 and SVR24. The cause of
death was  a complication of bowel obstruction.
4. Discussion
Patients with HCV-related advanced liver disease might benefit
from both TIPS placement and DAA therapy [6,8–12]. However, TIPS
leads to porto-systemic shunting [8] and its impact on drug phar-
macokinetics and consequently on efficacy and safety is uncertain.
While DAA therapy is generally safe in CHC and compensated cir-
rhosis [6,7], in patients with advanced liver disease, relevant rates
of SAE were observed [6,7]. In this study, we demonstrated for the
first time that patients with previous placement of TIPS can achieve
optimal rates of SVR24 (92.5%) and a significant decrease in MELD
and MELD-Na score from T0 to W24. In particular, both SVR rate
and the improvement of liver function in patients with prior place-
ment of TIPS treated with DAA are coherent with previous studies
in patients with advanced cirrhosis without TIPS [6,20]. It should be
noted that in patients with TIPS the decline of MELD was somehow
slower than in patients without TIPS. However, in patients with TIPS
a significantly higher delta-MELD than in patients without TIPS was
observed.
Notably, at two  years of follow-up, patients with and without
TIPS showed a comparable percentage of hard clinical outcomes
(LT and death). Surprisingly, patients with TIPS tended to develop a
lower number of DAA-related AEs and SAEs with respect to patientsransjugular Intrahepatic Portosystemic Shunt does not affect the
ed cirrhosis: A real-life, case-control study. Dig Liver Dis (2019),
without TIPS, although this difference was not significant. While it
is conceivable that the reduction in portal pressure could have an
impact on some of the AEs, data from larger series of patients are
necessary before definitive conclusions on this issue may  be drawn.
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We  also analyzed the whole population of patients with severe
iver disease, irrespective of TIPS, trying to identify independent
redictors of MELD increase from T0 to W24, and of AEs and SAEs.
ndeed, while in the majority of patients MELD score decreased
rom T0 to the end of follow-up (W24), in a subgroup of patients
he score increased (14.3% of patients with TIPS and 16.7% without
IPS). Elderly patients were at higher risk of MELD increase, con-
rming that age is a determinant of the likelihood to improve liver
unction, possible due to differences in hepatic functional reserve.
hese results are in agreement with those of Conti et al. [21], who
emonstrated that patients with advanced fibrosis or cirrhosis aged
65 years, and treated with DAA, had a worsening of CTP class, at
ifference from younger patients. Gender emerged as a borderline
redictor of the appearance of AE during DAA treatment. In fact,
ales showed four times as many AEs as females. Although this is
n original and potentially interesting finding, the low number of
emales enrolled in this study does not allow to draw any defini-
ive conclusions. Further studies should explore possible gender
ifferences in terms of SVR and safety profile in this population.
Patients with higher MELD score at T0 displayed a higher risk
f SAE. This finding is not surprising since only SAEs associated
ith advanced liver disease itself and not related to DAAs were
egistered. Notably, we could not analyze the possible predictors
f SVR or of transplant or death due to the low number of events.
We have to acknowledge a few limitations of this study, includ-
ng the relatively small number of patients enrolled. However,
his is the first real-life study analyzing whole laboratory, virolog-
cal, and clinical outcomes of patients treated with DAA after TIPS.
ecause DAAs have been introduced in clinical practice only few
ears ago, the length of follow-up reported in the present study (2
ears) is adequate to confirm the excellent results of DAA-based
herapy also in patients with advanced liver disease. The observa-
ional design of the study represents a further limitation, although
he 1:2 matching can assure an acceptable strength of the study
esign. The study adds real life-based knowledge in the context of
dvanced cirrhosis, a condition where additional post-registration
nformation may  still be of value [22]. Future studies should be
ndertaken to evaluate whether the outcomes observed in TIPS
atients treated with DAA are different from those of patients with
IPS not undergoing antiviral therapy. In the cohorts available in
ur centers, these latter patients had TIPS placed several years
efore and this would create a bias in the comparison. Another lim-
tation of this study is the lack of pharmacokinetic data in the two
roups of patients. These data, which could establish whether, and
o what extent, DAAs plasma levels are different in patients with
IPS, deserve to be obtained in future studies.
In conclusion, DAA-based antiviral therapy may  be safely and
ffectively used after TIPS placement. Cirrhotic patients with and
ithout TIPS treated with DAA have similar long-term outcomes
nd comparable chances to improve their liver function.
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